KORU Medical Systems (NASDAQ:KRMD) Earns “Neutral” Rating from Piper Sandler

KORU Medical Systems (NASDAQ:KRMD)‘s stock had its “neutral” rating restated by equities researchers at Piper Sandler in a research note issued on Friday, Marketbeat Ratings reports. They currently have a $4.50 target price on the stock. Piper Sandler’s target price suggests a potential upside of 2.97% from the company’s current price.

Other research analysts also recently issued reports about the stock. Canaccord Genuity Group boosted their price objective on shares of KORU Medical Systems from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Lake Street Capital raised their price objective on KORU Medical Systems from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, January 14th. Finally, Craig Hallum upped their target price on shares of KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $4.70.

KORU Medical Systems Stock Performance

NASDAQ:KRMD opened at $4.37 on Friday. The business has a 50 day moving average price of $4.16 and a 200-day moving average price of $3.23. The firm has a market cap of $200.31 million, a PE ratio of -17.48 and a beta of 0.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.99. KORU Medical Systems has a fifty-two week low of $2.01 and a fifty-two week high of $5.05.

Hedge Funds Weigh In On KORU Medical Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new stake in KORU Medical Systems in the 3rd quarter worth about $34,000. JPMorgan Chase & Co. boosted its holdings in shares of KORU Medical Systems by 2,770.7% during the 4th quarter. JPMorgan Chase & Co. now owns 17,712 shares of the company’s stock valued at $68,000 after acquiring an additional 17,095 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of KORU Medical Systems in the fourth quarter worth approximately $73,000. Y Intercept Hong Kong Ltd bought a new position in KORU Medical Systems during the fourth quarter valued at approximately $104,000. Finally, Raymond James Financial Inc. bought a new position in KORU Medical Systems during the fourth quarter valued at approximately $118,000. 58.60% of the stock is owned by institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.